Structure-Based Optimization of Small-Molecule Inhibitors for the β‑Catenin/B-Cell Lymphoma 9 Protein–Protein Interaction

Structure-based
optimization was conducted to improve the potency, selectivity, and
cell-based activities of β-catenin/B-cell lymphoma 9 (BCL9)
inhibitors based on the 4′-fluoro-N-phenyl-[1,1′-biphenyl]-3-carboxamide
scaffold, which was designed to mimic the side chains of the hydrophobic
α-helical hot spots at positions i, i + 3, and i + 7. Compound 29 was found to disrupt the β-catenin/BCL9 protein–protein
interaction (PPI) with a Ki of 0.47 μM
and >1900-fold selectivity for β-catenin/BCL9 over β-catenin/E-cadherin
PPIs. The proposed binding mode of new inhibitors was consistent with
the results of site-directed mutagenesis and structure–activity
relationship studies. Cell-based studies indicated that 29 disrupted the β-catenin/BCL9 interaction without affecting
the β-catenin/E-cadherin interaction, selectively suppressed
transactivation of Wnt/β-catenin signaling, downregulated expression
of Wnt target genes, and inhibited viability of Wnt/β-catenin-dependent
cancer cells in dose-dependent manners. A comparison of the biochemical
and cell-based assay results offered the directions for future inhibitor
optimization.